documents: FDA-2006-P-0025-0018
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2006-P-0025-0018 | FDA | FDA-2006-P-0025 | ICH Harmonised Tripartite Guidelines "Impurities in New Drug Products Q3B(R2)" - [Sanofi-aventis U.S., LLC (sanofi-aventis) - Petition Supplement(2)] | Supporting & Related Material | SUP-Supplement (Supporting and Related Material) | 2009-07-11T04:00:00Z | 2009 | 7 | 2009-07-11T09:15:59Z | 0 | 0 | 0900006480971bb1 |
Links from other tables
- 0 rows from regs_document_id in fr_regs_crossref